NCT05830084
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05830084
Title Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma (REGO-EWING)
Acronym REGO-EWING
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Gustave Roussy, Cancer Campus, Grand Paris
Indications
Therapies
Age Groups: adult | child
Covered Countries NLD | ITA | FRA | ESP | DNK | AUS

Facility Status City State Zip Country Details
Queensland Children's Hospital Brisbane Australia Details
Monash Children's Hospital Clayton Australia Details
Royal Children's Hospital Parkville Australia Details
Perth Children's Hospital Perth WA6009 Australia Details
Rigshospitalet Copenhagen DK-2100 Denmark Details
CHU Bordeaux Bordeaux France Details
Centre Oscar Lambret Lille France Details
centre Léon Bérard Lyon France Details
Institut Curie Paris France Details
Gustave Roussy Villejuif Île-de-France Region 94805 France Details
Istituto Nazionale dei Tumori Milan 20133 Italy Details
Princess Máxima Center Utrecht 113 Netherlands Details
Vall d'Hebron University Hospital Barcelona 119-12 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field